MCID: INV006
MIFTS: 49

Inverted Papilloma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Inverted Papilloma

MalaCards integrated aliases for Inverted Papilloma:

Name: Inverted Papilloma 12 15 70
Inverted Papilloma, Squamous Cell 12
Inverted Squamous Cell Papilloma 70
Papilloma, Inverted 44
Papilloma Inverted 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3179
MeSH 44 D018308
NCIt 50 C3793
SNOMED-CT 67 104081000119103
UMLS 70 C0206721 C1881254

Summaries for Inverted Papilloma

MalaCards based summary : Inverted Papilloma, also known as inverted papilloma, squamous cell, is related to squamous cell papilloma and frontal sinus inverted papilloma. An important gene associated with Inverted Papilloma is KRT13 (Keratin 13), and among its related pathways/superpathways are Endometrial cancer and Mitotic G1-G1/S phases. The drugs Bevacizumab and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include bone, endothelial and liver, and related phenotypes are digestive/alimentary and no phenotypic analysis

Wikipedia : 73 An inverted papilloma, also known as Ringertz tumour, is a type of tumor in which surface epithelial... more...

Related Diseases for Inverted Papilloma

Diseases related to Inverted Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 458)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 32.6 TP53 CDKN2A
2 frontal sinus inverted papilloma 32.4 KRT5 KRT13
3 urinary tract papillary transitional cell benign neoplasm 32.4 TP53 KRT20
4 bladder transitional cell papilloma 30.6 TP53 KRT20
5 in situ carcinoma 30.6 TP53 KRT5 EGFR CDKN2A
6 bladder urothelial carcinoma 30.6 TP53 KRT20 CDKN2A
7 keratosis 30.4 TP53 KRT5 CDKN2A
8 suppressor of tumorigenicity 3 30.4 TP53 CDKN2A
9 transitional cell carcinoma 30.4 TP53 MKI67 KRT7 KRT20 EGFR CDKN2A
10 papillary transitional carcinoma 30.3 TP53 KRT7 KRT20
11 cystitis 30.2 TP53 KRT7 KRT20
12 human papillomavirus infectious disease 30.2 TP53 KRT13 CDKN2A
13 verrucous carcinoma 30.0 TP53 KRT5 EGFR CDKN2A
14 squamous cell carcinoma 29.9 TP53 SERPINB4 MKI67 KRT7 EGFR CDKN2A
15 transitional papilloma 29.9 KRT7 KRT13
16 cystitis cystica 29.9 KRT7 KRT20 FSCN1
17 glandular cystitis 29.8 TP53 KRT7 KRT20 KRT13
18 papilloma 29.8 TP53 PCNA KRT7 KRT5 KRT20 KRT13
19 bladder cancer 29.7 TP53 MKI67 KRT20 EGFR CDKN2A CDKN1B
20 b-cell lymphoma 29.7 TP53 MKI67 CDKN2A CDKN1B
21 carcinosarcoma 29.6 TP53 KRT7 EGFR CDKN2A
22 sarcoma, synovial 29.6 MKI67 KRT7 KRT13
23 inverted transitional papilloma 29.5 KRT7 KRT5 CDKN2A
24 adenoma 29.5 TP53 MKI67 KRT7 KRT20 CDKN2A
25 adenocarcinoma 29.4 TP53 KRT7 KRT20 EGFR CDKN2A CDKN1B
26 basaloid squamous cell carcinoma 29.3 TP53 KRT7 KRT20 KRT13 EGFR CDKN2A
27 small cell carcinoma 29.3 TP53 KRT7 KRT20 EGFR CDKN2A
28 rhabdomyosarcoma 29.2 TP53 KRT7 EGFR CDKN2A CDKN1B
29 large cell carcinoma 29.2 KRT7 KRT5 KRT20 EGFR
30 oropharynx cancer 29.1 TP53 KRT7 KRT5 EGFR CDKN2A
31 renal cell carcinoma, nonpapillary 28.9 TP53 MKI67 KRT7 KRT20 EGFR CDKN1B
32 basal cell carcinoma 28.6 TP53 MKI67 KRT7 KRT5 KRT20 EGFR
33 mucoepidermoid carcinoma 28.3 TP53 PCNA MKI67 KRT7 KRT5 KRT13
34 maxillary sinus inverted papilloma 11.5
35 ureter inverted papilloma 11.5
36 sphenoid sinus inverted papilloma 11.4
37 urinary bladder inverted papilloma 11.4
38 urethra inverted papilloma 11.4
39 renal pelvis inverted papilloma 11.4
40 ethmoid sinus inverted papilloma 11.4
41 rare tumor 10.5
42 esophageal basaloid squamous cell carcinoma 10.4 TP53 EGFR
43 malignant peritoneal mesothelioma 10.4 EGFR CDKN2A
44 frontal lobe neoplasm 10.4 TP53 EGFR
45 vulvar intraepithelial neoplasia 10.4 TP53 CDKN2A
46 spinal cord oligodendroglioma 10.4 TP53 EGFR
47 spastic paraplegia, intellectual disability, nystagmus, and obesity 10.4
48 ameloblastic carcinoma 10.4 MKI67 CDKN2A
49 mammary analogue secretory carcinoma 10.4 TP53 EGFR
50 penile benign neoplasm 10.4 TP53 CDKN2A

Graphical network of the top 20 diseases related to Inverted Papilloma:



Diseases related to Inverted Papilloma

Symptoms & Phenotypes for Inverted Papilloma

MGI Mouse Phenotypes related to Inverted Papilloma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 CDKN1B CDKN2A EGFR KRT13 KRT5 MSX2
2 no phenotypic analysis MP:0003012 9.43 CDKN1B CDKN2A EGFR MKI67 PCNA TP53
3 pigmentation MP:0001186 9.1 CDKN1B CDKN2A EGFR FSCN1 MSX2 TP53

Drugs & Therapeutics for Inverted Papilloma

Drugs for Inverted Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
2
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
3
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
4
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
5 Angiogenesis Inhibitors Phase 1, Phase 2
6 Antineoplastic Agents, Immunological Phase 1, Phase 2
7 Protein Kinase Inhibitors Phase 1, Phase 2
8 Immunoglobulins Phase 1, Phase 2
9 Antibodies Phase 1, Phase 2
10 Immunoglobulins, Intravenous Phase 1, Phase 2
11 Antibodies, Monoclonal Phase 1, Phase 2
12 Immunologic Factors Phase 1, Phase 2
13
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
14 Neurotransmitter Agents Phase 1, Phase 2
15 Fluorides Phase 1, Phase 2
16 Fluorodeoxyglucose F18 Phase 1, Phase 2
17 Radiopharmaceuticals Phase 1, Phase 2
18 Arginyl-glycyl-aspartic acid Phase 1, Phase 2
19 N-Methylaspartate Phase 1, Phase 2
20
Arginine Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
21
Irinotecan Approved, Investigational Phase 1 100286-90-6, 97682-44-5 60838
22
Hydroxyurea Approved Phase 1 127-07-1 3657
23
Fluorouracil Approved Phase 1 51-21-8 3385
24
Lenograstim Approved, Investigational Phase 1 135968-09-1
25
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
26
Sirolimus Approved, Investigational Phase 1 53123-88-9 6436030 5284616
27
7-hydroxystaurosporine Experimental, Investigational Phase 1 112953-11-4 72271
28 topoisomerase I inhibitors Phase 1
29 Immunosuppressive Agents Phase 1
30 Antimetabolites Phase 1
31 Liver Extracts Phase 1
32 Cola Phase 1
33 Mitogens Phase 1
34 Endothelial Growth Factors Phase 1
35
Gefitinib Approved, Investigational 184475-35-2 123631

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
2 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
3 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
4 Phase 1 Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, NSC #707545) in Patients With Solid Tumors. Completed NCT00089362 Phase 1 alvespimycin hydrochloride
5 A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
6 A Phase I Study Of Bevacizumab (Recombinant Humanized Monoclonal Antibody To Vascular Endothelial Growth Factor) In Addition To Flourouracil And Hydroxyurea As Initial Chemotherapy With Concomitant Radiotherapy (B-FHX) For Poor Prognosis Head And Neck Cancer Completed NCT00023959 Phase 1 hydroxyurea;fluorouracil
7 A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) in Patients With Resectable, Primary or Recurrent Head and Neck Cancer Completed NCT00470496 Phase 1 HPPH;photodynamic therapy
8 A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
9 Phase I Study of OSI-774 (NSC 718781) for Solid Tumors in Patients With Hepatic or Renal Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
10 A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors Completed NCT01637194 Phase 1 everolimus
11 Image Guided Surgery in Sinonasal Inverted Papilloma by Targeting Vascular Endothelial Growth Factor Recruiting NCT03925285 Phase 1 Bevacizumab-800CW
12 Single Agent ZD-1839 (NSC-715055, IND-61187) in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger) Completed NCT00068497 gefitinib
13 Squamous Cell Carcinoma Antigen as a Marker of Sinonasal Inverted Papilloma Completed NCT01827423

Search NIH Clinical Center for Inverted Papilloma

Cochrane evidence based reviews: papilloma, inverted

Genetic Tests for Inverted Papilloma

Anatomical Context for Inverted Papilloma

MalaCards organs/tissues related to Inverted Papilloma:

40
Bone, Endothelial, Liver, Prostate, Pituitary, Kidney, Cervix

Publications for Inverted Papilloma

Articles related to Inverted Papilloma:

(show top 50) (show all 1386)
# Title Authors PMID Year
1
Expression of p53, p16INK4A, pRb, p21WAF1/CIP1, p27KIP1, cyclin D1, Ki-67 and HPV DNA in sinonasal endophytic Schneiderian (inverted) papilloma. 54 61
19863319 2009
2
Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp. 54 61
18544048 2008
3
Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. 54 61
18043040 2007
4
Possible prognostic significance of p53 and Ki 67 in inverted sinonasal papilloma. 61 54
17847937 2007
5
Increased expression of fascin associated with malignant transformation of sinonasal inverted papilloma. 54 61
17376306 2007
6
Immunohistochemical analysis of PCNA, Ki67 and p53 in nasal polyposis and sinonasal inverted papillomas. 54 61
17542411 2007
7
Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. 61 54
16084942 2005
8
Atypia in inverted urothelial papillomas: pathology and prognostic significance. 61 54
15619209 2004
9
[The relationship between tumor angiogenesis and cellular proliferation activity in nasal inverted papilloma]. 54 61
15571308 2004
10
[Inverted papilloma of the nose and paranasal sinuses--diagnosis, surgical procedure and studies of cytokeratin profile]. 61 54
9264595 1997
11
[Inverted transitional-cell papilloma: the expression of the Ki-67 nuclear antigen as a prognostic factor]. 61 54
8554393 1995
12
Malignant inverted papilloma of the urinary bladder: the histopathological aspect of malignant potential of inverted papilloma. 54 61
7576290 1995
13
Storz Professional Image Enhancement System (SPIES) endoscopy in the detection of sinonasal inverted papilloma: a pilot study. 61
33794734 2021
14
Inverted Nasal Papilloma Affecting Ears and Pulmonary Parenchyma: Case Report. 61
33811658 2021
15
Inverted Papilloma of the Orbit and Nasolacrimal System. 61
32501879 2021
16
Inverted urothelial papilloma: A rare pathology in young girl. A case report and literature review. 61
33384936 2021
17
[Confocal laser endomicroscopy - first application and validation of malignancy criteria]. 61
33772483 2021
18
Predicting Odontogenic Sinusitis in Unilateral Sinus Disease: A Prospective, Multivariate Analysis. 61
32646233 2021
19
Temporal bone primary inverted papilloma - Case Report and review of the literature. 61
33525009 2021
20
Updates in the cause of sinonasal inverted papilloma and malignant transformation to squamous cell carcinoma. 61
33337611 2021
21
Need for long-term follow-up in sinonasal inverted papilloma: A Single-institution experience. 61
33103314 2021
22
[Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder]. 61
33525029 2021
23
Sine Qua Non: Sinonasal Inverted Papilloma. 61
33544382 2021
24
Evaluation of Inflammatory Blood Markers in Sinonasal Inverted Papilloma. 61
33459561 2021
25
Comparison of Current Staging Systems for Sinonasal Inverted Papilloma. 61
32586102 2021
26
Genomic Sequencing of Cancer-related Genes in Sinonasal Squamous Cell Carcinoma and Coexisting Inverted Papilloma. 61
33419800 2021
27
The serum squamous cell carcinoma antigen level in inverted sinonasal papilloma and nasal polyps patients. 61
33474540 2021
28
Sinonasal inverted papilloma: rate of recurrence and malignant transformation in 44 operated patients. 61
31455578 2021
29
IMP3 Immunohistochemical Expression in Inverted Papilloma and Inverted Papilloma-Associated Sinonasal Squamous Cell Carcinoma. 61
33680717 2021
30
Presence of Tertiary Lymphoid Organ in Nasal Inverted Papilloma Is Correlated with Eosinophil Infiltration and Local Immunoglobulin Production. 61
33207352 2021
31
Expression of Sp100 Protein in Human Papillomavirus-Associated Sinonasal Inverted Papilloma. 61
31272209 2021
32
Prognostic Factors of Sinonasal Squamous Cell Carcinomas Arising De Novo and From Inverted Papilloma. 61
32659112 2021
33
Survival Outcomes of De Novo vs Inverted Papilloma-Associated Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. 61
33507208 2021
34
Recurrent inverted papilloma coexisted with skull base lymphoma: A case report. 61
33521124 2021
35
Endoscopic combined middle and inferior meatal antrostomies approach in treatment of maxillary sinus inverting papilloma. 61
33294081 2020
36
Inverted papilloma of the Oropharynx: A case of extrasinonasal inverted papilloma with an EGFR mutation. 61
32665183 2020
37
Establishment and characterization of an inverted papilloma-associated sinonasal squamous cell carcinoma cell line. 61
33252846 2020
38
Attachment-Oriented Endoscopic Treatment of Inverted Papilloma Involving the Frontal Sinus/Recess. 61
33136910 2020
39
Prelacrimal approach vs conventional surgery for inverted papilloma in the maxillary sinus. 61
32639072 2020
40
MRI Predictors of Malignant Transformation in Patients with Inverted Papilloma: A Decision Tree Analysis Using Conventional Imaging Features and Histogram Analysis of Apparent Diffusion Coefficients. 61
33289362 2020
41
Human papilloma virus induced oropharyngeal inverted papilloma as a precursor to laryngeal papillomatosis in A 1 year old child. 61
32896755 2020
42
Primary Heterotopic Meningioma of Nasal Cavity: Case Report and Literature Review. 61
33215534 2020
43
Endoscopic Denker's Approach for the Treatment of Extensive Sinonasal Tumors: Our Experience. 61
33140854 2020
44
A prelacrimal approach technique to overcome the limitation of the narrow lacrimal recess. 61
33188447 2020
45
Association Between Human Papilloma Virus Infection and Malignant Sinonasal Inverted Papilloma. 61
33111993 2020
46
Can Computed Tomography Findings Predict the Recurrence of Sinonasal Inverted Papilloma? 61
33048600 2020
47
The role of human papillomavirus in the pathogenesis of sinonasal inverted papilloma: a narrative review. 61
33048407 2020
48
DIAGNOSIS AND TREATMENT OF PATIENTS WITH SINONASAL INVERTED PAPILLOMA. 61
33130642 2020
49
Endoscopic transsphenoidal approach to a sphenoid sinus inverted papilloma combined with pituitary adenoma: a case report. 61
32940105 2020
50
Epiphora and unrecognized paranasal sinuses pathology. 61
32671284 2020

Variations for Inverted Papilloma

Cosmic variations for Inverted Papilloma:

9 (show top 50) (show all 166)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM112988925 HRAS urinary tract,bladder,papilloma,inverted c.181C>A p.Q61K 11:533875-533875 4
2 COSM91331243 HRAS urinary tract,bladder,papilloma,inverted c.181C>A p.Q61K 11:533875-533875 4
3 COSM101951686 HRAS urinary tract,bladder,papilloma,inverted c.181C>A p.Q61K 11:533875-533875 4
4 COSM101967342 HRAS urinary tract,bladder,papilloma,inverted c.181C>A p.Q61K 11:533875-533875 4
5 COSM105721476 HRAS urinary tract,bladder,papilloma,inverted c.181C>A p.Q61K 11:533875-533875 4
6 COSM102794588 FGFR3 urinary tract,bladder,papilloma,inverted c.742C>T p.R248C 4:1801837-1801837 4
7 COSM90922619 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 4:1801891-1801891 4
8 COSM102817661 FGFR3 urinary tract,bladder,papilloma,inverted c.1545G>T p.E515D 4:1806095-1806095 4
9 COSM90920128 FGFR3 urinary tract,bladder,papilloma,inverted c.1242C>T p.H414= 4:1804490-1804490 4
10 COSM107633928 FGFR3 urinary tract,bladder,papilloma,inverted c.1927C>G p.H643D 4:1806141-1806141 4
11 COSM142951575 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259= 4:1801870-1801870 4
12 COSM90912543 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259= 4:1801870-1801870 4
13 COSM91805120 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259= 4:1801870-1801870 4
14 COSM91816713 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 4:1801840-1801840 4
15 COSM115719540 FGFR3 urinary tract,bladder,papilloma,inverted c.1960A>C p.N654H 4:1806171-1806171 4
16 COSM107634786 FGFR3 urinary tract,bladder,papilloma,inverted c.1236C>T p.H412= 4:1804490-1804490 4
17 COSM90932095 FGFR3 urinary tract,bladder,papilloma,inverted c.1887G>T p.E629D 4:1806095-1806095 4
18 COSM107637911 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 4:1801840-1801840 4
19 COSM91802800 FGFR3 urinary tract,bladder,papilloma,inverted c.742C>T p.R248C 4:1801837-1801837 4
20 COSM142956265 FGFR3 urinary tract,bladder,papilloma,inverted c.*292C>T p.? 4:1804490-1804490 4
21 COSM102796829 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259= 4:1801870-1801870 4
22 COSM115718544 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 4:1801840-1801840 4
23 COSM90919415 FGFR3 urinary tract,bladder,papilloma,inverted c.1933C>G p.H645D 4:1806141-1806141 4
24 COSM102810810 FGFR3 urinary tract,bladder,papilloma,inverted c.1621A>C p.N541H 4:1806171-1806171 4
25 COSM115714115 FGFR3 urinary tract,bladder,papilloma,inverted c.1930C>G p.H644D 4:1806141-1806141 4
26 COSM102804555 FGFR3 urinary tract,bladder,papilloma,inverted c.1591C>G p.H531D 4:1806141-1806141 4
27 COSM115705346 FGFR3 urinary tract,bladder,papilloma,inverted c.742C>T p.R248C 4:1801837-1801837 4
28 COSM115707354 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259= 4:1801870-1801870 4
29 COSM90923995 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 4:1801840-1801840 4
30 COSM102805364 FGFR3 urinary tract,bladder,papilloma,inverted c.931-334C>T p.? 4:1804490-1804490 4
31 COSM115717305 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 4:1801891-1801891 4
32 COSM91811841 FGFR3 urinary tract,bladder,papilloma,inverted c.1591C>G p.H531D 4:1806141-1806141 4
33 COSM90925211 FGFR3 urinary tract,bladder,papilloma,inverted c.1963A>C p.N655H 4:1806171-1806171 4
34 COSM142951584 FGFR3 urinary tract,bladder,papilloma,inverted c.*977G>A p.? 4:1806135-1806135 4
35 COSM107627424 FGFR3 urinary tract,bladder,papilloma,inverted c.775C>T p.L259= 4:1801870-1801870 4
36 COSM91823729 FGFR3 urinary tract,bladder,papilloma,inverted c.1545G>T p.E515D 4:1806095-1806095 4
37 COSM142960037 FGFR3 urinary tract,bladder,papilloma,inverted c.*1013A>C p.? 4:1806171-1806171 4
38 COSM102807783 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 4:1801891-1801891 4
39 COSM142959260 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 4:1801840-1801840 4
40 COSM91814789 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 4:1801891-1801891 4
41 COSM91805129 FGFR3 urinary tract,bladder,papilloma,inverted c.1585G>A p.D529N 4:1806135-1806135 4
42 COSM142958229 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 4:1801891-1801891 4
43 COSM107639326 FGFR3 urinary tract,bladder,papilloma,inverted c.1957A>C p.N653H 4:1806171-1806171 4
44 COSM115707366 FGFR3 urinary tract,bladder,papilloma,inverted c.1924G>A p.D642N 4:1806135-1806135 4
45 COSM90912554 FGFR3 urinary tract,bladder,papilloma,inverted c.1927G>A p.D643N 4:1806135-1806135 4
46 COSM107645165 FGFR3 urinary tract,bladder,papilloma,inverted c.1881G>T p.E627D 4:1806095-1806095 4
47 COSM91817950 FGFR3 urinary tract,bladder,papilloma,inverted c.1621A>C p.N541H 4:1806171-1806171 4
48 COSM107636650 FGFR3 urinary tract,bladder,papilloma,inverted c.796G>A p.V266M 4:1801891-1801891 4
49 COSM107627432 FGFR3 urinary tract,bladder,papilloma,inverted c.1921G>A p.D641N 4:1806135-1806135 4
50 COSM102809609 FGFR3 urinary tract,bladder,papilloma,inverted c.745T>A p.S249T 4:1801840-1801840 4

Expression for Inverted Papilloma

Search GEO for disease gene expression data for Inverted Papilloma.

Pathways for Inverted Papilloma

Pathways related to Inverted Papilloma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.62 TP53 PCNA EGFR CDKN2A CDKN1B
2
Show member pathways
12.36 TP53 PCNA CDKN2A CDKN1B
3
Show member pathways
12.27 KRT7 KRT5 KRT20 KRT13
4 12.21 TP53 FSCN1 EGFR CDKN2A CDKN1B
5 12.14 KRT7 KRT5 KRT20 KRT13 FSCN1
6 12.06 TP53 PCNA CDKN2A CDKN1B
7 12.02 TP53 PCNA MKI67 CDKN2A CDKN1B
8 11.87 TP53 PCNA EGFR
9 11.82 TP53 EGFR CDKN1B
10 11.79 TP53 CDKN2A CDKN1B
11
Show member pathways
11.76 KRT7 KRT5 KRT13
12
Show member pathways
11.71 TP53 PCNA CDKN1B
13 11.62 TP53 PCNA CDKN1B
14 11.5 PCNA MKI67 CDKN1B
15 11.47 TP53 EGFR CDKN2A
16 11.3 TP53 EGFR CDKN2A CDKN1B
17 11.25 TP53 EGFR CDKN2A
18 10.95 TP53 PCNA CDKN2A CDKN1B

GO Terms for Inverted Papilloma

Cellular components related to Inverted Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.73 TP53 PCNA MT2A MSX2 MKI67 KRT7
2 nuclear body GO:0016604 9.56 TP53 PCNA MKI67 CDKN2A
3 keratin filament GO:0045095 9.33 KRT7 KRT5 KRT13
4 intermediate filament GO:0005882 8.92 KRT7 KRT5 KRT20 KRT13

Biological processes related to Inverted Papilloma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.77 TP53 PCNA KRT7 IFI27 EGFR
2 cell cycle arrest GO:0007050 9.72 TP53 CDKN2A CDKN1B
3 response to oxidative stress GO:0006979 9.7 TP53 PCNA EGFR
4 negative regulation of cell growth GO:0030308 9.67 TP53 CDKN2A CDKN1B
5 response to estradiol GO:0032355 9.61 PCNA EGFR CDKN1B
6 negative regulation of phosphorylation GO:0042326 9.54 CDKN2A CDKN1B
7 response to lipid GO:0033993 9.51 PCNA EGFR
8 mitotic cell cycle arrest GO:0071850 9.48 TP53 CDKN1B
9 replicative senescence GO:0090399 9.46 TP53 CDKN2A
10 keratinization GO:0031424 9.46 KRT7 KRT5 KRT20 KRT13
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.43 TP53 PCNA CDKN1B
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 TP53 EGFR
13 regulation of protein export from nucleus GO:0046825 9.32 IFI27 CDKN2A
14 negative regulation of mitotic cell cycle GO:0045930 9.13 TP53 EGFR CDKN1B
15 cornification GO:0070268 8.92 KRT7 KRT5 KRT20 KRT13

Molecular functions related to Inverted Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CDKN2A CDKN1B
2 protein phosphatase binding GO:0019903 9.13 TP53 EGFR CDKN1B
3 MDM2/MDM4 family protein binding GO:0097371 8.62 TP53 CDKN2A

Sources for Inverted Papilloma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....